Literature DB >> 9314468

Hepatitis A among homosexual men and injection drug users: more evidence for vaccination.

S A Villano1, K E Nelson, D Vlahov, R H Purcell, A J Saah, D L Thomas.   

Abstract

As agencies develop guidelines for administering the newly developed hepatitis A virus (HAV) vaccine, information is needed regarding the occurrence of HAV infection in groups putatively at risk for the infection. We tested serum samples from 300 injection drug users (IDUs), 300 homosexual males, and 300 blood donors for the presence of total antibody to HAV (anti-HAV). Anti-HAV was detected in 66% of IDUs, 32% of homosexual males, and 14% of blood donors. Anti-HAV was not significantly associated (P > .10) with high-risk drug-using behaviors but was more prevalent among IDUs with annual incomes of <$5,000 (P = .018). The occurrence of anti-HAV increased among homosexual males as the number of sexual partners increased (P < .001) but was similar to the age-adjusted prevalence (30.6%) estimated for the general United States population. IDUs are at increased risk for HAV infection; however, our data suggest that factors related to low socioeconomic status contribute more to the occurrence of HAV infection among IDUs than does injection drug use. IDUs and persons at risk for injection drug use should receive HAV vaccine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314468     DOI: 10.1086/513757

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

Review 1.  Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration.

Authors:  Sandro Galea; David Vlahov
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

2.  Molecular epidemiology of hepatitis A virus in metropolitan areas in Japan.

Authors:  Hideaki Takahashi; Hiroshi Yotsuyanagi; Kiyomi Yasuda; Tomohiko Koibuchi; Michihiro Suzuki; Tomohiro Kato; Tetsuya Nakamura; Aikichi Iwamoto; Kusuki Nishioka; Shiro Iino; Kazuhiko Koike; Fumio Itoh
Journal:  J Gastroenterol       Date:  2006-11-09       Impact factor: 7.527

3.  Integrating hepatitis services into substance abuse treatment programs: new initiatives from SAMHSA.

Authors:  Thomas F Kresina; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

4.  Hepatitis A in primary care: working in partnership for diagnosis, management, and prevention of outbreaks.

Authors:  Antiopi Ntouva; Bharat Sibal; Koye Balogun; Sema Mandal; Nick Harding
Journal:  Br J Gen Pract       Date:  2019-09-26       Impact factor: 5.386

Review 5.  Sexual transmission and prevention of the hepatitis viruses A-E and G.

Authors:  M G Brook
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

6.  Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002.

Authors:  Miriam Gerlich; Patrick Gschwend; Ambros Uchtenhagen; Alexander Krämer; Jürgen Rehm
Journal:  Eur J Epidemiol       Date:  2006-07-21       Impact factor: 8.082

Review 7.  Hepatitis A: old and new.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

8.  Seroprevalence of hepatitis A immunity in male genitourinary medicine clinic attenders: a case control study of heterosexual and homosexual men.

Authors:  J D C Ross; M Ghanem; A Tariq; G Gilleran; A J Winter
Journal:  Sex Transm Infect       Date:  2002-06       Impact factor: 3.519

9.  Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis.

Authors:  Erik Seth Kramer; Charlotte Hofmann; Paula G Smith; Mitchell L Shiffman; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

10.  Hepatitis A seroprevalence and risk factors among homeless adults in San Francisco: should homelessness be included in the risk-based strategy for vaccination?

Authors:  Karen A Hennessey; David R Bangsberg; Cindy Weinbaum; Judith A Hahn
Journal:  Public Health Rep       Date:  2009 Nov-Dec       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.